Health-Related Quality of Life in Amyotrophic Lateral Sclerosis: Determining a Meaningful Deterioration Article DOI:
Cite this article as: Norquist, J.M., Fitzpatrick, R. & Jenkinson, C. Qual Life Res (2004) 13: 1409. doi:10.1023/B:QURE.0000040786.75103.3a Abstract
This paper uses the standard error of measurement (SEM) and the standard error of the difference (
S diff) in relation to data on individuals with amyotrophic lateral sclerosis (ALS) to calculate the minimum change scores required by statistical criteria for each dimension of the Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40). Data collected from a longitudinal study was used to evaluate the usefulness of SEM and S diff criteria and to compare these criteria with an anchor-based approach in determining meaningful change. Questionnaires were completed on two occasions, 3 months apart. 764 questionnaires were returned. Questionnaires included the ALSAQ-40 and dimension specific transition items. The ALSAQ-40 is a disease specific health-related quality of life instrument for use in studies of patients with ALS or other motor neuron diseases. For all dimensions of the ALSAQ-40 the patterns of SEMs were similar over time. The results suggest that, for example, six points change on a 0–100 transformed scoring of the physical mobility dimension may be considered on distributional grounds a minimum meaningful change. The demonstrated consistency of SEMs for the dimensions of the ALSAQ-40 is empirical evidence of the theoretically claimed advantage of this measure of sample independence, and supports use of this distributional approach to calculate meaningful change. ALSAQ-40 Amyotrophic lateral sclerosis Change scores Clinical significance Meaningful change Quality of life References
Benzimon JT, Lacomblez L, Meininger V, ALS/riluzole Study Group.A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585–591.
Clancy C, Eisenberg J. Outcomes research: Measuring the end results of health care. Science 1998; 282: 245–246.
Deyo RA, Patrick DL. Barriers to the use of health status measures in clinical investigation, patient care, and policy research. Med Care 1989; 27(3 Suppl): S254–S268.
Lydick E, Epstein RS. Interpretation of quality of life changes. Qual Life Res 1993; 2(3): 221–226.
Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989; 27(3 Suppl): S178–S189.
Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and statistical signi cance in evaluating intra-individual changes in health-related quality of life. Med Care 1999; 37(5): 469–478.
Wyrwich KW, Tierney WM, Wolinsky FD. Further evi-dence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999; 52(9): 861–873.
Nunnally J, Bernstein SJ. Psychometric Theory. New York, USA: McGraw Hill, 1994.
Iverson GL. Interpreting change on the WAIS-III/WMS-III in clinical samples. Arch Clin Neuropsychol 2001; 16: 183–191.
Jacobson N, Follette W, Revenstorf D. Psychotherpay outcomes research: Methods for reporting variability and evaluating clinical signi cance. Behav Therapy 1984; 15: 336–352.
Ferguson RJ, Robinson AB, Splaine M. Use of the reliable change index to evaluate clinical signi cance in SF-36 outcomes. Qual Life Res 2002; 11: 509–516.
Cella D, Eton D, Fairclough D,et al. What is a clinically meaningful change on the Functional Assessment of Cancer–Lung (Fact-L)Questionnaire?Results from Eastern Cooperative Oncology Group (ECOG)Study 5592. J Clin Epidemiol 2002; 55: 285–295.
Juniper EF, Guyatt GH, Willan A, Griffith LE. Deter-mining a minimal important change in a disease-speci c Quality of Life Questionnaire. J Clin Epidemiol 1994; 47(1): 81–87.
Crosby R, Kolotkin R, Williams G. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003; 56: 395–407.
Guyatt GH, Norman GR, Juniper EF, Griffith LE. A critical look at transition ratings. J Clin Epidemiol 2002; 55(9): 900–908.
Jenkinson C, Fitzpatrick R, Brennan C, Bromberg M, Swash M. Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/motor neurone disease: The ALSAQ-40. J Neurol 1999; 246(3 Suppl): III16–III21
Kiebert GW, Green C, Murphy C, et al. Patients 'health-related quality of life and utilities associated with different stages of amyotrophic lateral sclerosis. J Neurol Sci 2001; 191: 87–93.
Jenkinson C, Fitzpatrick R, Brennan C, Swash M. Evi-dence for the validity and reliability of the ALS Assessment Questionnaire: The ALSAQ-40. Amyotroph Lateral Scler Other Motor Neuron Disord 1999; 1: 33–44.
Jenkinson C, Levvy G, Fitzpatrick R, Garratt A. The Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40): Tests of data quality, score reliability and response rate in a survey of patients. J Neurol Sci 2000; 180(1–2): 94–100.
Jenkinson C, Fitzpatrick R, Swash M, Levvy G. ALSAQ User Manual–Amyotrophic Lateral Sclerosis Assessment Questionnaire. Oxford: Health Services Research United., 2001.
Jenkinson C, Peto V, Jones G, Fitzpatrick R. Interpreting change scores on the Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40). Clin Rehabil 2003; 17: 380–385.
Fitzpatrick R, Ziebland S, Jenkinson C, Mowat A, Mowat A. Transition questions to assess outcomes in rheumatoid arthritis. Br J Rheumatol 1993; 32(9): 807–811.
Jenkinson C, Norquist JM, Fitzpatrick R. Deriving sum-mary indices of health status from the Amyotrophic Lateral Sclerosis Assessment Questionnaires (ALSAQ-40 and AL-SAQ-5). J Neurol Neurosurg Psychiat 2003; 74(2): 242–245.
Wyrwich KW, Tierney RM, Wolinsky FD. Using the standard error of measurement to identify important changes on the Asthma Quality of Life Questionnaire. Qual Life Res 2002; 11(2): 1–7.
Google Scholar Copyright information
© Kluwer Academic Publishers 2004